Climb Bio
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
20 William St Ste 145, Wellesley Hills, ...Phone Number
(866) 857-2596Website
www.climbbio.comRevenue
$10.6 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Climb Bio
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapies for immune-mediated diseases. Its pipeline targets B-cell and immune pathways to address conditions with significant unmet medical needExplore more
Climb Bio Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Climb Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Climb Bio has new funding data
Congratulate Masked Content for being promoted to Masked Content at Climb Bio
Check out if Climb Bio is spiking on competitors!
Earning: See what the market has to say on Climb Bio recently announced quarterly report
Check if Climb Bio has recently received funding, and reach out quickly before it becomes old news!
Click to see if Climb Bio had a recent Job posting/layoffs
Product Launch: Get notified when Climb Bio launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Climb Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Climb Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Climb Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Climb Bio.
Climb Bio financials insights
Gather financial insights about Climb Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Private Equity
$110.1M
Climb Bio Tech Stack
A closer look at the technologies used by Climb Bio
See more technologies
Most Recent Scoops
Funding
Funding
Open Position
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Climb Bio News & Media
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summerClimb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026.Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026.Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Climb Bio
Sign Up For FreeTo access detailed company insights
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody therapies for immune-mediated diseases. Its pipeline targets B-cell and immune pathways to address conditions with significant unmet medical need... Read More
